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要　旨
２０１５年に日本で承認された新医療用製剤に対し、安定性試験の現状を調査した。我々は、２０１５年に安
定性試験の記述がある８１の新医療用製剤を特定した。長期保存試験としては、５　 製剤が３０±２℃/６５±
５％相対湿度の条件下で、５５製剤が２５±２℃/６０±５％相対湿度の条件下で、２１製剤が５±３℃の条件
下で試験が実施されていた。また、加速性試験では、６０製剤が４０±２℃/７５±５％相対湿度の条件下で
実施されていた。１７製剤は２５±２℃/６０±５％相対湿度の条件下で実施された。３　 製剤は温度及び試験
期間がマスキングされていて、不明であった。１　 製剤は半減期が短いため、加速試験は実施されなかっ
た．これらの結果から、２０１５年に日本で承認された新医療用製剤は、１　 つを除いて ICH ガイドライン
に従って、適正に承認されていることがわかった。
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Abstract
This study aimed to examine the current status of stability testing for new drug products in 
Japan.　Among the ８１ new drug products that stability testing in ２０１５, ５, ５５ and ２１ were tested 
at ３０℃±２℃/６５％±５％ relative humidity（RH）, ２５℃±２℃/６０％±５％ RH, and ５℃±３℃, respectively. 
In accelerated testing, ６０ and １７ products were tested at ４０℃±２℃/７５％±５％RH and ２５℃±２℃/６０ 
％±５％RH, respectively; additionally, the test conditions were unknown for ３ products, whereas １ 
product was not tested because of its short half-life.　Based on these results, all new drug products, 
except the one that was not tested, approved by the Japanese government in ２０１５ according to the 
International Council on Harmonisation of Technical Requirements for Registration of Pharmaceu- 
ticals for Human Use guidelines performed adequately in stability testing.
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原　著　論　文 
Introduction
Recently, international harmonization of 
examination documents concerning pharma-
ceutical approval examination documents has 
been promoted to accelerate pharmaceutical 
research and development and to ensure that 
products can be quickly supplied to patient. 
Thus, the International Council on Harmoni-
sation of Technical Requirements for Registra-
tion of Pharmaceuticals for Human Use（ICH）
was established and promoted to support these 
efforts.
Stability test results are prerequisite re-
quirements for new drug applications.　There-
fore, ICH specifies many guidelines for stabili- 
ty testing of new drug products, as listed in 
Table １.１５）
ICHQ１A（R２）states that the stability 
data package for new drug substances or prod-
ucts is sufficient for registration application 
in Japan, the United States, and the European 
Union.１）
ICHQ１B states that the intrinsic photo-
stability characteristics of new drug sub-
stances and products should be evaluated to 
demonstrate that light exposure does not cause 
any unacceptable change.２）
ICHQ１C is an annex to ICHQ１A（R２）
that specifies guidelines regarding data on the 
stability of new dosage forms that should be 
submitted by the original applicant after the 
initial registration applicant for new drug sub-
stances and products.３）
ICHQ１D provides guideline on the appli-
cation of bracketing and matrixing in stability 
studies.４）
ICHQ１E guides on the use stability data 
that is generated in accordance with ICHQ１A
（R２）to propose retest periods or to estimate 
the shelf life in a registration application.５） 
In addition, this guideline describes when and 
how extrapolation can be considered when pro-
posing a retest period for a drug substance 
or estimating the shelf life of a drug product 
that extends beyond the period specified in 
“available data from stability studies under 
long-term storage conditions”.５）
In new drug applications, long-term and 
acceleration studies must be included in sta-
bility testing according to ICHQ１A（R２）.
In the present study, data obtained from 
the stability testing of drug products approved 
by the Japanese government in ２０１５ were ana-
lyzed and discussed.
MATERIALS AND METHODS
Drugs approved between January and De-
cember ２０１５ were surveyed.　Information 
sources for stability data included data summa-
ries［Module ２ of Common Technical Docu- 
ment（CTD）in the present system］, which 
were submitted by the applicants for new drug 
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Table １　ICH guidelines for stability testing of new drug products
AbbreviationGuideline name
ICHQ１A（R２）Stability Testing of New Drug Substances and Products
ICHQ１BStability Testing: Photostability Testing of New Drug Substances and Products
ICHQ１CStability Testing for New Dosage Forms
ICHQ１DBracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products
ICHQ１EEvaluation of Stability Data
application, and approval documents, which de-
scribed specifications and test methods for 
drug substances.　This information, particu-
larly that in the quality sections, is not entirely 
publicly available, although Module ２ of the 
CTD and review reports are available on the 
Internet.６）　Therefore, the identities of the indi-
vidual drug substances whose stability data 
were examined in this study were not disclosed.
RESULTS AND DISCUSSION
Classification of Approved Drugs Accord- 
ing to Stability Testing
In total ２３３ new drug products, excluding 
antiseptics for medical devices, in vivo diagnos-
tics, and generic drugs, were approved by the 
Japanese government in ２０１５.　Of these, stabil-
ity testing was performed for ８１ new drug 
products, which represented a ６０％ decline com-
pared with that performed for new drug prod-
ucts in ２０１４.７）　These products included ６４ 
novel drugs, ３ with new prescription combi-
nation preparations, ５ with new administra-
tion routs, ４ with new indications, ３ with new 
formulations, and ２ with new dosages or other 
drug types.（Fig. １）
Further, we investigated the details of the 
８１ new drug products
Long-term Testing
Long-term testing was performed for ５, 
５５, and ２１ new drug products at ３０℃±２℃/６５％
±５％ relative humidity（RH）, ２５℃±２℃/６０％
±５％RH, and ５℃±３℃, respectively（Table 
２）.
According to ICHQ１A（R２）１）, long-term 
testing for general new drug products should 
be performed at ２５℃±２℃ /６０％±５％ RH or 
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Fig. １　Stability testing of new drug products of the following application categories
Ａ: Drug with a new ingredient
Ｂ: New prescription combination preparation
Ｃ: Drug with a new route of administration
Ｄ: Drug with a new indication and/or others
Ｅ: Drug with a new formulation
Ｆ: Drug with a new dosage and other types of drugs
３０℃±２℃/６５％±５％RH, and accelerated test-
ing for general new drug products should be 
performed at ４０℃±２℃/７５％±５％RH.　In the 
case of new drug products requiring refrigera-
tion, long-term testing is performed at ５℃± 
３℃ and accelerated testing at ２５℃±２℃/６０％
±５％RH.　For new drug products requiring 
storage in a freezer, long-term testing is per-
formed at －２０℃±５℃.　In addition, long-term 
testing for drug products requiring storage 
at temperature ＜－２０℃ is performed on a case-
by-case basis.
For these new drug products, the exami- 
nation periods were ＞３６ months, ２４ months, 
１８ months, １２ months, １４ days for ２９, ３５, １４, 
１, and １ products, respectively; masking was 
employed for １ product（Table ２）.　The exami-
nation periods satisfied the minimum duration 
recommended by ICHQ１A１ for all but one 
new drug product.　Because this one new drug 
product was radioactive and has a short half-
life, we believe masking it was appropriate.
Stability data for ３６ new drug products 
were evaluated using ICHQ１E５） and post-
poned the expiration date（Fig. ２）.
According to ICHQ１D４, ５ new drug prod-
ucts were evaluated using a bracketing method 
for stability testing.　ICHQ１A１ and ICH 
Q１D４ specify a bracketing method for different 
container sizes or fills in the same container clo-
sure system.　This methods is rarely applied 
because it is not necessary in stability testing 
data of new drug products.　The potential risk 
of excluding this method is that a shorter shelf 
life than that derived from a full design may be 
established due to the reduced amount of data 
collected４）.
Accelerated Testing
Accelerated testing was performed for the 
８１ new drug products（Table ３）.
Accelerated testing, a part of formal stabil-
ity study, increases the rate of chemical deg-
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Table ２　Storage conditions and examination periods for the ８１ new drug products
Number of new drug products testedExamination periodsStorage Condition
２３６ months
３０℃±２℃/６５％±５％RH １２４ months
２１８ months
６６０ months
２５℃±２℃/６０％±５％RH
１４８ months
１２３６ months
２９２４ months
６１８ months
１１２ months
２６０ months
５℃±３℃
６３６ months
５２４ months
６１８ months
１１４ days
１Masking
radation or physical change of a drug product 
using exaggerated storage conditions.１）　These 
data can be used to assess long-term chemical 
effects within a drug products under non-ac-
celerated conditions and to evaluate the effects 
of short-term deviations from the labeled stor-
age conditions, such as those occurring during 
shipping.１）　Even if the results of accelerated 
testing deviate from the specified values, they 
do not influence the approval.
In conclusion, this review described the 
８１ new drug products approved by the Japa-
nese government in ２０１５ according to ICH 
guidelines, all of which performed ade-
quately in stability testing.
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Fig. ２　Proportion of new drug products applications with and without ICHQ１E data
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